DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $260

RBC Capital maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $240 to $260.

Benzinga · 01/31/2020 15:36

RBC Capital maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $240 to $260.